Tedisamil

From Self-sufficiency
Jump to: navigation, search
Tedisamil
File:Tedisamil.svg
Systematic (IUPAC) name
3,7-bis(cyclopropylmethyl)-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,1'-cyclopentane]
Identifiers
CAS Number 90961-53-8
ATC code C01BD06 (WHO)
PubChem CID 65825
Chemical data
Formula C19H32N2
Molar mass 288.470 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Tedisamil (planned trade name Pulzium) is an investigational class III antiarrhythmic for atrial fibrillation and atrial flutter. It is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administration.

On April 25, 2007, Solvay submitted a New Drug Application for tedisamil, and on December 12, 2007, the Cardio-Renal Advisory Committee of the FDA voted against approval of tedisamil, at this time, requesting that Solvay Pharmaceuticals provides additional information to the FDA.[1]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


it:Tedisamil pt:Tedisamila
  1. "Drugs.com, Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation". Retrieved 2008-03-15.